Alyeska Investment Group, L.P. Gain Therapeutics, Inc. Transaction History
Alyeska Investment Group, L.P.
- $16.5 Billion
- Q2 2024
A detailed history of Alyeska Investment Group, L.P. transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Alyeska Investment Group, L.P. holds 450,000 shares of GANX stock, worth $670,500. This represents 0.0% of its overall portfolio holdings.
Number of Shares
450,000Holding current value
$670,500% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding GANX
# of Institutions
31Shares Held
3.75MCall Options Held
0Put Options Held
0-
Timelo Investment Management Inc.605KShares$901,8790.45% of portfolio
-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$876,7300.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$843,5330.04% of portfolio
-
Hohimer Wealth Management, LLC330KShares$491,7000.1% of portfolio
-
Geode Capital Management, LLC Boston, MA184KShares$273,7660.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $17.7M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...